Redhill Biopharma Ltd (RDHL.OQ)
17 Oct 2018
Mon, Jul 30 2018
TEL AVIV Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.
TEL AVIV, July 30 Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.
* REDHILL BIOPHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS
BRIEF-Redhill Biopharma Says Last Patient Assessed For Main Goal In Late-Stage Crohn's Disease Trial
* REDHILL BIOPHARMA ANNOUNCES LAST PATIENT ASSESSED FOR PRIMARY ENDPOINT IN RHB-104 PHASE III STUDY FOR CROHN’S DISEASE
BRIEF-RedHill Biopharma Reports Enrollment of 300th Patient in Confirmatory Phase III Study With Talicia
* REDHILL BIOPHARMA ANNOUNCES ENROLLMENT OF 300TH PATIENT IN CONFIRMATORY PHASE III STUDY WITH TALICIA® FOR H. PYLORI INFECTION
- Your Daily Pharma Scoop: FibroGen Fast Tracked, Dr. Reddy's Entry, Bristol-Myers Succeeds
- Your Daily Pharma Scoop: Spectrum Positive, Xenon Expands, ViiV's Label Receives FDA Clearance
- RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon
- RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q2 2018 Results - Earnings Call Transcript
- RedHill Biopharma: Current Dip An Opportunity?
- Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review